Pfizer's preliminary analysis of its COVID-19 antiviral pill provided very high success rates. Pfizer's CEO has spoken of his company's pill as a "game-changer." Is he right? How might this pill affect the stock prices of Pfizer and its competitors, as well as the broader market?
Moderna stock hit a record high on Monday as global vaccination programs ramped up. Last Thursday’s earning release also showed that the biotech company made $4.4 billion in revenue in the second quarter of 2021.